Navigation Links
Neurobiological Technologies Sets Date for First Quarter Financial Results
Date:11/4/2008

EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its first quarter 2009 financial results, for the quarter ended September 30, 2008, and host a conference call on November 6, 2008.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President and Chief Financial Officer. The details for the call are as follows:

Live Call:

-- Date: Thursday, November 6, 2007

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 800-309-1245 (U.S.) 719-457-2080 (International)

Webcast of Call:

-- A live webcast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: (Archived for 90 days)

A playback of the conference call will be available from 1:30 PM November

6 (ET) through midnight November 13 (ET).

Replay number: 888-203-1112 (U.S. and Canada) / 719-457-0820

(international).

Replay access code: 8094663.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
3. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
6. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies CEO to Retire on December 31, 2008
8. Neurobiological Technologies Reports Third Quarter Financial Results
9. Neurobiological Technologies Sets Date for Third Quarter Financial Results
10. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
11. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... TX (PRWEB) , ... April 21, 2017 , ... Having ... than a year, Formaspace is pleased to introduce it to top lab design architects ... Formaspace CEO Jeff Turk and VP of Industrial Design and Engineering Greg Casey will ...
(Date:4/21/2017)... ... ... The AMA is happy to announce that $48,000 in scholarships will be awarded ... created through funds donated by model aviation organizations and individuals, AMA members, and a ... Committee, which is made up of model aviation pilots and enthusiasts. The committee evaluates ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... new webinar will explore challenging patient cases when screening for direct oral anticoagulant. ... may be a need for bridging parental anticoagulation especially for those at high ...
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... USDM ... for the life sciences and healthcare industries, is pleased to announce Holger Braemer ... established USDM subsidiary “USDM Europe GmbH” based in Germany. , Braemer is an ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):